Author:
Nolan Terry M.,Richmond Peter C.,Skeljo Maryanne V.,Pearce Georgina,Hartel Gunter,Formica Neil T.,Höschler Katja,Bennet Jillian,Ryan David,Papanaoum Kelly,Basser Russell L.,Zambon Maria C.
Subject
Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine
Reference17 articles.
1. World Health Organisation. Cumulative number of confirmed human cases of avian influenza A (H5N1) reported to WHO; February 12, 2008. http://www.who.int/csr/disease/avian_influenza/country/en/(accessed February 14, 2008).
2. Committee for Proprietary Medicinal Products (CPMP). Guideline on dossier structure and content for pandemic influenza vaccine marketing authorisation application (CPMP/VEG/4717/03). London: European Agency for the Evaluation of Medicinal Products (EMEA); April 5, 2004.
3. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial;Bresson;Lancet,2006
4. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial;Lin;Lancet,2006
5. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine;Treanor;N Engl J Med,2006